Gufic Biosciences Limited (BOM: 509079)

Market Cap	44.79B
Revenue (ttm)	8.04B
Net Income (ttm)	849.28M
Shares Out	100.28M
EPS (ttm)	8.47
PE Ratio	52.70
Forward PE	n/a
Dividend	0.10 (0.02%)
Ex-Dividend Date	Sep 17, 2024

Volume	14,436
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	272.75 - 501.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,491
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.